Evidence map›Paper›PMID 25963271›Full record

ReviewNature reviews. Endocrinology2015

Insights from exome sequencing for endocrine disorders.

Christiaan de Bruin, Andrew Dauber

Abstract readReview
In one paragraph

Review in Nature reviews. Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Search for Novel Mutational Targets in Human Endocrine Diseases.Endocrinology and metabolism (Seoul, Korea) · 2019
    Review
  5. An update of genetic basis of PCOS pathogenesis.Archives of endocrinology and metabolism · 2018
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. SRC-2 orchestrates polygenic inputs for fine-tuning glucose homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christiaan de BruinCincinnati Children's Hospital Medical Center, Division of Endocrinology, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Andrew DauberCincinnati Children's Hospital Medical Center, Division of Endocrinology, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.

Funding

Rare Genetic Variants as Novel Causes of Idopathic or Syndromic Short StatureK23HD073351 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI DAUBER, ANDREW NAHUM · 2012 to 2016
$664k
NICHD NIH HHS 1K23HD073351NICHD NIH HHS K23 HD073351
6 · The paper itself

Abstract

Whole-exome sequencing has emerged as a fast and effective tool for the elucidation of genetic defects underlying both rare and common human diseases. Increased availability and decreased costs of next-generation sequencing have enabled investigators to use this approach not only in individual patients with rare diseases, but also to screen large cohorts or populations for the genetic determinants of diseases. Within the field of endocrinology, exome sequencing has led to major advancements in our understanding of many disorders including adrenal disease, growth and puberty disorders and type 2 diabetes mellitus, as well as a multitude of rare genetic syndromes with prominent endocrine involvement. In this Review, we provide an overview of these new insights and discuss the role that exome sequencing is expected to have in endocrine research and future clinical practice.

Indexed as

Endocrine System DiseasesExomeHigh-Throughput Nucleotide SequencingHumansSequence AnalysisSexual Maturation

Identifiers

PMID25963271
PMCPMC4806650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.